严重急性呼吸综合征冠状病毒2感染对原发性中枢神经系统淋巴瘤治疗结局的影响:国际原发性中枢神经系统淋巴瘤协作组研究
该国际系列纳入91例原发性中枢神经系统淋巴瘤合并SARS-CoV-2感染患者,其中64例在初治前/中感染,38例(59%)发生肺炎、26例(41%)病毒未清除;感染前/中延长激素暴露及大剂量阿糖胞苷治疗与肺炎发生、病毒持续及较差生存相关,病毒未清除者81%早期死于COVID-19;疫苗接种与较低肺炎发生率和院内死亡率相关;43例(67%)启动/恢复化疗,病毒持续者恢复化疗与较差生存相关(6个月生存率70%对87%,p=0.07)。
要点
- 初治前/中感染SARS-CoV-2的64例中,38例(59%)发生肺炎、26例(41%)病毒未清除。
- 病毒未清除者81%早期死于COVID-19;疫苗接种与较低肺炎发生率和院内死亡率相关。
- 病毒持续者恢复化疗与较差生存相关(6个月生存率70%对87%,p=0.07)。
核心结论
- 在原发性中枢神经系统淋巴瘤合并SARS-CoV-2感染患者中,感染前/中延长激素暴露及大剂量阿糖胞苷治疗与肺炎发生、病毒持续及较差生存相关。
- 病毒未清除者81%早期死于COVID-19;疫苗接种与较低肺炎发生率和院内死亡率相关。
- 病毒持续者恢复化疗与较差生存相关(6个月生存率70%对87%,p=0.07),应谨慎指示。
研究设计与样本
- 国际多中心系列研究,纳入91例原发性中枢神经系统淋巴瘤合并SARS-CoV-2感染患者。
- SARS-CoV-2诊断时机:64例在初治前/中,21例在随访期间,6例在挽救治疗期间。
主要发现
- 初治前/中感染的64例中,38例(59%)发生肺炎,26例(41%)病毒未清除。
- 感染前/中延长激素暴露和/或大剂量阿糖胞苷治疗与肺炎发生、病毒持续及较差生存相关。
- 病毒未清除者81%早期死于COVID-19;疫苗接种与较低肺炎发生率和院内死亡率相关。
- 43例(67%)启动或恢复化疗,更多见于未发生肺炎、病毒清除或感染期间未接受激素者。
- 病毒持续者恢复化疗与较差生存相关(6个月生存率70%对87%,p=0.07)。
关键数值与推荐
- 初治前/中感染64例中,肺炎38例(59%),病毒未清除26例(41%)。
- 病毒未清除者81%早期死于COVID-19。
- 化疗启动/恢复43例(67%)。
- 病毒持续者恢复化疗的6个月生存率70%对87%,p=0.07。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To optimise management of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection identifying high-risk patients and maintaining treatment dose intensity is an important issue in patients with aggressive lymphomas. In the present study, we report on the presentation, management, and outcome of an international series of 91 patients with primary central nervous system lymphoma and SARS-CoV-2 infection. SARS-CoV-2 was diagnosed before/during first-line treatment in 64 patients, during follow-up in 21, and during salvage therapy in six. Among the 64 patients infected before/during first-line chemotherapy, 38 (59%) developed pneumonia and 26 (41%) did not clear the virus. Prolonged exposure to steroids before viral infection and/or treatment with high-dose cytarabine favoured pneumonia development and virus persistence and were associated with poorer survival; 81% of patients who did not clear virus died early from coronavirus disease 2019 (COVID-19). Vaccination was associated with lower pneumonia incidence and in-hospital mortality. Chemotherapy was initiated/resumed in 43 (67%) patients, more commonly among patients who did not develop pneumonia, cleared the virus, or did not receive steroids during infection. Chemotherapy resumption in patients with viral persistence should be indicated cautiously as it was associated with a poorer survival (6-month, 70% and 87%, p = 0.07). None of the 21 patients infected during follow-up died from COVID-19, requiring similar measures as infected subjects in the general population.
引用
- Steffanoni S, Calimeri T, Laurenge A, et al. Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group. Br J Haematol. 2022. PMID: 35945164. doi:10.1111/bjh.18396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。